
|Articles|July 1, 2004
Genaera begins more squalamine trials
Genaera Corp. will begin three phase II trials on squalamine, its systemically administered anti-angiogenic drug.
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Genaera Corp. will begin three phase II trials on squalamine, its systemically administered anti-angiogenic drug.